FDA Warns Chinese API Maker for False Batch Records

Drug GMP Report
A Chinese active pharmaceutical ingredient (API) maker was slammed by the FDA for falsifying batch record signoffs and product labeling, the latest international drugmaker to be caught in the agency’s crackdown on poor data integrity.

To View This Article:


Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $40.00